Latest Intelligence on Pharmaceuticals and Healthcare in Fiji

Select information type

Refine your search

search
Search tips

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

BMS: combination pill rejection is yet another setback

Although this decision is unlikely to have a significant impact on Pravachol sales, it's still disappointing for BMS. It needs any revenue boost it can get this year, as sales of many of its other blockbuster drugs plummet. The FDA decision may also affect other players that plan to market single pills containing compounds for different indications, including Pfizer.

Published By Datamonitor
23 Jan 2002

« | 1 | » »|

No help is available.